
Commentary|Videos|April 8, 2024
The Inclisiran Impact on PCSK9: A Primary Care Primer
Author(s)Grace Halsey
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Advertisement
Michael J Koren, MD, primary investigator of the VICTORION-INITIATE study of an "inclisiran first" strategy to reduce LDL-C in individuals with ASCVD, differentiates the small-interfering RNA molecule from other agents that reduce the impact of PCSK9 on the cardiovascular system.
Michael J Koren, MD, primary investigator of the VICTORION-INITIATE study, is a cardiologist and serves as the chief executive officer at ENCORE Research Group, in Jacksonville, FL. Koren founded ENCORE in 1997 and since then the organization has conducted more than 2500 clinical trials across 8 locations in Florida.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Avoiding Common Ordering Errors in UACR Testing, With Holly Kramer, MD
2
Nationwide Survey Finds Widespread Concern About Topical Steroid Use, Emphasizes Need for Long-Term Management Strategies in Chronic Inflammatory Skin Disease
3
Healthiest States in America: A 2025 Ranking
4
Sebela Submits NDA for Tegoprazan for GERD, Seeking Approval for NERD and Erosive Esophagitis
5























































































































































































































































































































